BCA
ARRY

Bay Colony Advisors’s Array Biopharma Inc ARRY Stock Holding History

Bay Colony Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100
Closed -$2K – 1006
2018
Q2 		$2K Buy
+100
New +$1.59K ﹤0.01% 884

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Bay Colony Advisors's ARRY Position: Q3 2018 in Review

Bay Colony Advisors sold out of Array Biopharma Inc (ARRY) in Q3 2018, closing a stake of 100 shares — an estimated $2K sold.

Bay Colony Advisors first reported a position in ARRY in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 208 funds tracked by Wall St. Rank hold ARRY as of Q3 2018.

  • Bay Colony Advisors reported no remaining Array Biopharma Inc position as of Q3 2018 after selling out during the quarter.
  • Bay Colony Advisors sold 100 Array Biopharma Inc shares in Q3 2018, an estimated $2K.
  • Bay Colony Advisors first reported a position in Array Biopharma Inc in Q2 2018 and held it in 1 quarter.
  • Bay Colony Advisors's Array Biopharma Inc position peaked at $2K in Q2 2018.
  • 208 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2018.

Based on Bay Colony Advisors's 13F filing for Q3 2018, filed 5 Nov 2018.